1. Home
  2. DMRC vs VYGR Comparison

DMRC vs VYGR Comparison

Compare DMRC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Digimarc Corporation

DMRC

Digimarc Corporation

HOLD

Current Price

$6.53

Market Cap

183.5M

Sector

Technology

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.20

Market Cap

203.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DMRC
VYGR
Founded
2008
2013
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
183.5M
203.6M
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
DMRC
VYGR
Price
$6.53
$3.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$10.00
$16.50
AVG Volume (30 Days)
195.5K
752.4K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$34.04
Revenue Next Year
N/A
$7.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.07
$2.88
52 Week High
$17.47
$5.55

Technical Indicators

Market Signals
Indicator
DMRC
VYGR
Relative Strength Index (RSI) 32.59 36.04
Support Level $6.13 N/A
Resistance Level $7.10 $4.33
Average True Range (ATR) 0.76 0.19
MACD -0.06 -0.05
Stochastic Oscillator 4.12 14.97

Price Performance

Historical Comparison
DMRC
VYGR

About DMRC Digimarc Corporation

Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: